US 8133870
Therapeutic furopyrimidines and thienopyrimidines
granted A61KA61K31/675A61K31/7076
Quick answer
US patent 8133870 (Therapeutic furopyrimidines and thienopyrimidines) held by BioCryst Pharmaceuticals, Inc. expires Mon Mar 08 2032 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- BioCryst Pharmaceuticals, Inc.
- Grant date
- Tue Mar 13 2012 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Mar 08 2032 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 24
- CPC classes
- A61K, A61K31/675, A61K31/7076, A61K38/212, A61K38/2292